SENS: Future Commercial Rollout Will Drive Diabetes Monitoring Adoption

Key Takeaways

• Strong product innovation, strategic partnerships, and expanded insurance coverage position Senseonics for sustained revenue growth and improved profitability in the evolving CGM market.
  
• Enhanced patient access and direct-to-consumer efforts support higher adoption, better retention, and increased recurring revenue potential as demand for advanced diabetes care solutions rises.
  
• Continued reliance on a single core product, operational losses, shifting revenue cycles, reimbursement uncertainties, and nascent ecosystem partnerships pose significant risks to sustained growth.

Catalysts

A commercial-stage medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally.

• The rising prevalence of diabetes globally, particularly among type 2 patients, is accelerating the transition from traditional glucose monitoring to continuous glucose monitoring (CGM) solutions; Senseonics' focus on expanding Eversense 365 and initiating direct-to-consumer campaigns is poised to drive broad-based, long-term revenue growth as the addressable market continues to expand.
  
• Increased emphasis in healthcare on preventive care and outcomes has led to improved insurance reimbursement and growing Medicare and commercial payer adoption of bundled payments for Eversense 365, directly supporting both higher utilization rates and expanding gross margins in the medium-to-long-term.
  
• Ongoing product innovation-specifically, the upcoming Gemini (self-powered, wear-optional sensor) and Freedom (fully invisible CGM) platforms-demonstrates sustained R&D investment, positioning Senseonics to maintain differentiation and increase average selling prices, which can drive future revenue and long-term earnings growth.
  
• Strengthened distribution partnerships, particularly with Ascensia and new pump manufacturers (such as the integration with Sequel's twiist pump), are scaling fixed costs and improving operational leverage, which should support both topline growth and operating margin expansion as sales volumes increase.
  
• Expansion of the Eon Care inserter network and streamlined provider access are targeting key obstacles to adoption, further enhancing patient growth, improving retention rates, and potentially increasing recurring revenues as more patients remain on the platform for multiple annual cycles.

Senseonics Holdings Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming Senseonics Holdings's revenue will grow by 54.6% annually over the next 3 years.
• Analysts are not forecasting that Senseonics Holdings will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Senseonics Holdings's profit margin will increase from -214.2% to the average US Medical Equipment industry of 11.9% in 3 years.
• If Senseonics Holdings's profit margin were to converge on the industry average, you could expect earnings to reach $17.9 million (and earnings per share of $0.4) by about June 2029, up from -$87.2 million today.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 43.6x on those 2029 earnings, up from -3.6x today. This future PE is greater than the current PE for the US Medical Equipment industry at 25.9x.
• Analysts expect the number of shares outstanding to grow by 2.61% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.7%, as per the Simply Wall St company report.

Risks

• Senseonics remains highly reliant on a single product platform (Eversense CGM system), and while new developments like Gemini and Freedom are in the pipeline, any delay in their clinical validation, regulatory approval, or commercial launch could leave the company exposed to both market-share erosion and decelerating revenue growth if competitors introduce superior offerings.
  
• The company continues to operate at a net loss ($14.5 million net loss in Q2 2025), and despite a strengthened balance sheet post capital raise, ongoing cash burn and reliance on equity funding (potentially including a reverse stock split to maintain investor compliance) risk future shareholder dilution and may constrain long-term earnings per share (EPS).
  
• The shift to a 12-month sensor cycle for Eversense reduces order frequency and has resulted in lower reorder volumes in the mid-year quarters, creating seasonal lulls in revenue and increasing dependency on successful patient retention and re-insertion rates to sustain long-term recurring revenues.
  
• Although Medicare and some private payers are converting to bundled payment models, any reversal in reimbursement policies or slower-than-expected adoption by commercial insurers could impact pricing, patient access, and net margins, especially if healthcare cost containment pressures grow.
  
• Strategic partnerships and integration with insulin pumps (like Sequel's twiist) are still in early stages, and failure to secure or effectively execute additional alliances may limit Senseonics' ability to compete in an ecosystem where interoperability and comprehensive digital health solutions are increasingly favored-potentially constraining revenue growth and future market share.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of $13.8 for Senseonics Holdings based on their expectations of its future earnings growth, profit margins and other risk factors.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $20.0, and the most bearish reporting a price target of just $8.0.
• In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $150.4 million, earnings will come to $17.9 million, and it would be trading on a PE ratio of 43.6x, assuming you use a discount rate of 7.7%.
• Given the current share price of $5.94, the analyst price target of $13.8 is 57.0% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.